logo

COVID-19: Drugs in Development

Share

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
Moderna, Inc
(MRNA)
mRNA-1273 Vaccine
Phase 2 study to begin in Q2, 2020
Phase 3 study to begin in July 2020
BARDA
05/19/2020
Sanofi
( SNYNF, SNY)
Kevzara (Repurposed drug)
Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced “critical” group with Kevzara higher-dose versus placebo and discontinuing less advanced “severe” group
-
Regeneron Pharmaceuticals, Inc. (REGN)
05/16/2020
InflaRx N.V.
(IFRX)
IFX-1 for COVID-19 pneumonia
Phase 2 trial of IFX-1 in COVID-19 patients with severely progressed pneumonia in Netherlands
-
Beijing Defengrei Biotechnology Co. Ltd.
05/16/2020
Amgen Inc.
(AMGN)
Otezla (Repurposed drug)
Psoriasis drug Otezla to be tested as a potential treatment for COVID-19
-
-
05/11/2020
Mesoblast Limited
(MESO)
Remestemcel-L
Phase 2/3 trial of Remestemcel-L for COVID-19 acute respiratory distress syndrome
-
Mount Sinai Hospital in New York
05/11/2020
AstraZeneca PLC
(AZN.L, AZN)
Farxiga (Repurposed drug)
Phase 3 trial of Farxiga as a treatment in patients hospitalised with COVID-19 who are at risk of developing serious complications, such as organ failure (DARE-19)
-
Saint Luke’s Mid America Heart Institute
05/10/2020
Cyclacel Pharmaceuticals Inc.
( CYCCP, CYCC)
Fadraciclib and Seliciclib
Clinical stage drug candidates Fadraciclib and Seliciclib to be tested as potential early treatments for inflammatory response observed in COVID-19 patients
-
University of Edinburgh
05/10/2020
Alnylam Pharmaceuticals Inc.
(ALNY)
RNAi therapeutics for COVID-19
VIR-2703, also known as ALN-COV, identified as lead inhaled RNAi treatment for COVID-19
VIR-2703 (ALN-COV) to enter human trial around end of 2020
Vir Biotechnology Inc. (VIR)
05/04/2020

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Latam Airlines Group SA, one of the largest air carrier in South America, has filed for bankruptcy protection in New York amid the ongoing Covid-19 pandemic, which has grounded flights worldwide. This Chapter 11 filing allows Latam to work with its creditors and other stakeholders to reduce its debt,... Pizza Hut said it is giving away 500,000 free pizzas to 2020 graduates in the Unites States. The pizza chain, owned by Yum! Brands, offers one free medium 1-topping pizza to all diploma/degree earning individuals until supplies last. The company is partnering with America's dairy farmers for the offer, which can be claimed until Thursday and redeemed until June 4. Merck & Co. Inc. on Tuesday announced deals, including an acquisition and two collaborations that will enable the U.S. drugmaker to join the race to develop coronavirus vaccines and drugs. Shares of Merck were rising almost 4 percent in the pre-market. Merck said it has agreed to acquire privately-held Themis, an Austria-based company focused on vaccines and immune-modulation therapies.